Adrian Folkes

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel et al. · Molecular Cancer Therapeutics · 2009 · 274 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

Michael W. Roe, Adrian Folkes, Philip J. Ashworth et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 164 citations

Medicine, Medicinal Chemistry, Pharmacology +11

Novel Angular Benzophenazines:  Dual Topoisomerase I and Topoisomerase II Inhibitors as Potential Anticancer Agents

Nigel Vicker, Luke Burgess, Irina Chuckowree et al. · Journal of Medicinal Chemistry · 2002 · 133 citations

Medicine, Medicinal Chemistry, Pharmacology +9

Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Daniel P. Sutherlin, Deepak Sampath, Megan Berry et al. · Journal of Medicinal Chemistry · 2010 · 131 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17